These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31816083)

  • 1. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
    Bermudez MV; Papa S
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities associated with checkpoint inhibitors-an overview.
    Spiers L; Coupe N; Payne M
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunology and melanoma immunotherapy.
    Linck RDM; Costa RLP; Garicochea B
    An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging Cases: Management of Immune-Related Toxicity.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
    Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
    J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
    Warner AB; Postow MA
    Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
    Levine O; Devji T; Xie F
    Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.